edoc

Kras in metastatic colorectal cancer

Wicki, Andreas and Herrmann, Richard and Christofori, Gerhard. (2010) Kras in metastatic colorectal cancer. Swiss Medical Weekly, Vol. 140 , w13112.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6006769

Downloads: Statistics Overview

Abstract

Kras, a small intracellular GTPase, is a central intermediary of the epidermal growth factor receptor (EGFR) and other tyrosine kinase receptor pathways. Increased EGFR and Kras signalling is involved in colorectal carcinogenesis and tumour progression. Mutations of Kras result in the loss of its GTPase activity and thus in a constitutive activation of Kras signalling. Kras mutations are found in 30-60% of colorectal cancers. The concordance between Kras mutations in the primary tumour and related metastatic sites is high. Since mutation of Kras confers resistance to anti-EGFR-antibody therapy, it is critical to assess Kras mutational status in colorectal cancer patients. Anti-EGFR-antibody therapy improves survival in patients with metastatic colorectal cancer and wild-type Kras.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Onkologie (Herrmann)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Onkologie (Herrmann)
03 Faculty of Medicine > Departement Biomedizin > Division of Biochemistry and Genetics > Tumor Biology (Christofori)
UniBasel Contributors:Christofori, Gerhard M. and Herrmann, Richard
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:EMH
ISSN:1424-7860
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:01 Feb 2013 08:46
Deposited On:01 Feb 2013 08:44

Repository Staff Only: item control page